- Home
- XBIO vs ATNF Comparison
XBIO vs ATNF Comparison
Compare XBIO & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- ATNF
- Stock Information
- Founded
- XBIO N/A
- ATNF 2016
- Country
- XBIO United States
- ATNF United States
- Employees
- XBIO N/A
- ATNF N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- ATNF Health Care
- Exchange
- XBIO Nasdaq
- ATNF Nasdaq
- Market Cap
- XBIO 4.2M
- ATNF 3.8M
- IPO Year
- XBIO N/A
- ATNF N/A
- Fundamental
- Price
- XBIO $2.91
- ATNF $1.18
- Analyst Decision
- XBIO Hold
- ATNF
- Analyst Count
- XBIO 1
- ATNF 0
- Target Price
- XBIO N/A
- ATNF N/A
- AVG Volume (30 Days)
- XBIO 9.5K
- ATNF 234.0K
- Earning Date
- XBIO 05-13-2025
- ATNF 05-27-2025
- Dividend Yield
- XBIO N/A
- ATNF N/A
- EPS Growth
- XBIO N/A
- ATNF N/A
- EPS
- XBIO N/A
- ATNF N/A
- Revenue
- XBIO $2,582,728.00
- ATNF N/A
- Revenue This Year
- XBIO $14.23
- ATNF N/A
- Revenue Next Year
- XBIO N/A
- ATNF N/A
- P/E Ratio
- XBIO N/A
- ATNF N/A
- Revenue Growth
- XBIO 5.63
- ATNF N/A
- 52 Week Low
- XBIO $2.20
- ATNF $0.66
- 52 Week High
- XBIO $5.20
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- XBIO 49.56
- ATNF 59.10
- Support Level
- XBIO $2.78
- ATNF $1.08
- Resistance Level
- XBIO $3.22
- ATNF $1.24
- Average True Range (ATR)
- XBIO 0.24
- ATNF 0.17
- MACD
- XBIO 0.03
- ATNF 0.02
- Stochastic Oscillator
- XBIO 34.16
- ATNF 54.90
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.